Suscriptores   Asóciese  
Textos Completos Autorizados
MEMANTINA

v-estudie-lo-mejor.gif
Expertos Invitados




Artículos relacionadosArtículos relacionadosArtículos relacionados
Artículos afines de siicsalud publicados en los últimos 4 meses
USO REGULAR DE LAXANTES Y DEMENCIA
Neurology 100(16):1702-1711
Difundido en siicsalud: 22 feb 2024
DONANEMAB EN LA ENFERMEDAD DE ALZHEIMER PRECOZ SINTOMÁTICA
JAMA 330(6):512-527
Difundido en siicsalud: 21 dic 2023

MEMANTINA

(especial para SIIC © Derechos reservados)
La memantina es un fármaco neuroprotector en la EA y la demencia vascular.
Autor:
José L. Molinuevo Guix
Columnista Experto de SIIC

Institución:
Unidad Memoria-Alzheimer Instituto Clínico de Enfermedades del Sistema Nervioso (ICMSN) Hospital Clínico Universitario

Artículos publicados por José L. Molinuevo Guix
Coautor
Albert Lladó Plarrumaní* 
Licenciado en Medicina. Unitat Memoria-Alzheimer, Servei de Neurologia, Institut Clínic de Neurociències, Hospital Clínic i Provincial de Barcelona*
Recepción del artículo
17 de Marzo, 2005 		Aprobación
6 de Abril, 2005
Primera edición
27 de Octubre, 2005 		Segunda edición, ampliada y corregida
7 de Junio, 2021

MEMANTINA

Resumen
La enfermedad de Alzheimer (EA) es la forma más frecuente de demencia en los países occidentales. Los beneficios que se observan con los tratamientos actualmente aprobados son fundamentalmente sintomáticos sin evidencia clara de neuroprotección. Los antagonistas del receptor del N-metil-D-aspartato (NMDA) presentan potencial terapéutico para el tratamiento de varias enfermedades del sistema nervioso central, incluyendo la neuroprotección de enfermedades neurodegenerativas crónicas y el tratamiento sintomático de otras enfermedades neurológicas. La memantina, un antagonista del NMDA, ha sido recientemente aprobado para el tratamiento de la EA avanzada. Por su mecanismo de acción la memantina se considera un fármaco neuroprotector, cuya utilidad se demostró en estudios preclínicos. Asimismo, la memantina es un tratamiento sintomático útil en la EA y la demencia vascular. En esta revisión se analizan ambos aspectos de la memantina, al igual que los mecanismos básicos implicados en la cognición y en la neurodegeneración glutamatérgica.

Palabras clave
Memantina, enfermedad de Alzheimer, demencia, NMDA, tratamiento neuroprotector


Artículo completo
(castellano)
Extensión:  +/-6.77 páginas impresas en papel A4
Exclusivo para suscriptores/assinantes
Clasificación en siicsalud
Artículos originales > Expertos de Iberoamérica >
página   www.siicsalud.com/des/expertocompleto.php/

Especialidades
Principal: Neurología
Relacionadas: Farmacología, Medicina Familiar, Medicina Farmacéutica, Medicina Interna



Comprar este artículo
Extensión: 6.77 páginas impresas en papel A4

file05.gif (1491 bytes) Artículos seleccionados para su compra



Bibliografía del artículo
  1. Lobo A, Launer LJ, Fratiglioni L y col. Prevalence of dementia a major subtypes in Europe: a collaborative study of population-based cohorts. Neurology Diseases in the Ederly Research Group. Neurology 2000; 54 (11 suppl. 5):S4-S9.
  2. Launer LJ, Hofman A. Frequency and impact of neurologic in the elderly of Europe: a collaborative study of population-based cohorts. Neurology 2000; 54 (11 suppl. 5):S1-S8.
  3. Hebert LE, Scherr PA, Bienias JL, Bennet DA, Evans DA. Alzheimer disease in the US population. Prevalence estimates using the 2000 census. Arch Neurol 2003; 60:119-1122.
  4. Schenk D, Barbour R, Dunn W y col. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 1999; 400:173-7.
  5. Kilpatrick GJ, Tilbrook GS. Memantine. Curr Opin Investig Drugs 2002; 3:798-806.
  6. Mayeux R, Sano M. Treatment of Alzheimer’s disease. N Engl J Med 1999; 341:1670-1679.
  7. Winblad B, Möbius HJ, Stöfler A. Glutamate receptor as a target for Alzheimer’s disease, are clinical results supporting the hope. J Neural Transm 2002; 62(supl):217-225.
  8. Danysz W, Parsons CG, Bresink I, Quack G. Glutamate in CNS disorders: a revived target for drug development Drug News Perspect 1995; 8:261-277.
  9. Müller WE, Mutschler E, Riederer P. Noncompetitive NMDA receptor antagonists with fast open channel kinetics and strong voltage dependency as potential therapeutic agents for Alzheimer’s dementia. Pharmacopsychiatry 1995; 28:113-24.
  10. Rothman SM, Olney JW. Excitotoxicity and the NMDA receptors. Trends Neurosci 1987; 10:299-302.
  11. Jain KK. Evaluation of memantine for neuroprotection in dementia. Expert Opin Investig Drugs 2000; 9:1397-1406.
  12. Rammsayer TH. Effects of pharmacologically induced changes in NMDA-receptor activity on long term memory in humans. Learn Mem 2001; 8:20-5.
  13. Danysz W, Parsons CG, Möbius HG y col. Neuroprotection and symptomatological action of memantine relevant for Alzheimer’s disease: a unified hypothesis on the mechanisms of action. Neurotox Res 2000; 2:85-98.
  14. Danysz W, Parsons CG. The NMDA receptor antagonist memantine as a symptomatological and neuroprotective treatment for Alzheimer’s disease: preclinical evidence. Int J Geriatr Psychiatry 2003; 18 (suppl 1):S23-S32.
  15. Thompson RF, Kim JJ. Memory systems in the brain and localization of a memory. Proc. Natl. Acad. Sci. 1996; 93 (24):13438-44.
  16. Baudry M, Davis JL eds. (1991) Long-term potentiation: A debate of current issues (MIT Press, Cambridge, MA).
  17. Lynch G, Baudry M. The biochemistry of memory: a new and specific hypothesis. Science 1984; 224 (4653):1057-63.
  18. Landfield PW, Deadwyler SA eds. (1988) Long-term potentiation: A debate of current issues (MIT Press, Cambridge, MA).
  19. Baudry M, Thompson RF, Davis JL eds. (1993) Synaptic plasticity, molecular, cellular, and functional aspects (MIT Press, Cambridge, MA).
  20. Masliah E, Mallory M, Aldford M y col. Caspase dependent DNA fragmentation might be associated with excititoxicity in Alzheimer’s disease. J Neuropathol Exp Neurol 1998; 57:1041-52.
  21. Li S, Mallory M, Aldford M, Tanaka S y col. Glutamate transporter alteration in Alzheimer’s disease are possibly associated with abnormal APP expression. J Neuropathol Exp Neurol 1997; 56:901-11.
  22. Arias C, Arrieta I, Tapia R. Beta amyloid peptide fragment potentiates the calcium dependent release of excitatory amino acids from depolarized hippocampal slices. J Neurosci Res 1995; 41:561-6.
  23. Wu JQ, Anwyl R, Rowan MJ. Beta amyloid selectively augments NMDA receptor-mediated synaptic transmission in rat hyppocampus. Neuroreport 1995: 2409-13.
  24. Couratier P, Sindou P, Tabarud E y col. Modulation of tau neuronal expression induced by NMDA, non-NMDA and metabotropic glutamate receptor agonists. Neurodegeneration 1995; 4:33-41.
  25. Kornhuber J, Quack G. Cerebrospinal fluid and serum concentrations of the N-methyl-D-aspartate (NMDA) receptor antagonist memantine in man. Neurosci. Lett. 1995; 195:137-9.
  26. Graham SM, Jonas JM, Lee GS, Goetz MA, Stöffler A, Wirth Y. Memantine is safe for short- and long-term treatment of dementia. Neurobiology of aging 2004; 25:195.
  27. Sobolevsky A, Koshelev SG, Khorodov BI. Interaction of memantine and amantadine with agonist unbound NMDA receptor channels in acutely isolated rat hippocampal neurons. J Physiol 1998; 512:47-60.
  28. Parsons CG, Danysz W, Quack G. Memantine and the amino-alkyl-cyclohexane MRZ 2/579 are moderate affinity uncompetitive NMDA receptor antagonists in vitro characterization. Amino Acids 2000; 19:157-66.
  29. Berger W, Deckert J, Hartmann J y col. Memantine inhibits [3H]MK-801 binding to human hippocampal NMDA receptors. Neuroreport. 1994; 5 (10):1237-40.
  30. Frankiewicz T, Parsons CG. Memantine restores long term potentiation impaired by tonic N-methyl-D-aspartate (NMDA) receptor activation following reduction of Mg+2 in hippocampal slices. Neuropharmacology 1999; 38:1253-9.
  31. Pellegrini JW, Lipton SA. Delayed administration of memantine prevents N-methyl-D-aspartate receptor-mediated neurotoxicity. Ann Neurol 1993; 33:403-7.
  32. Lahiri DK, Alley GM, Morgan C, Banerjee PK, Farlow MR. Effects of memantine on kevels of the amyloid beta peptide in cell cultures. Eur Neuropsychopharmacol 2003; 13(Suppl 4):S391.
  33. Lahiri DK, Bailey J, Alley GM, Chen D, Sambamurti K, Greig N. Effects of diverse cholinesterase inhibitors and memantine on the amyloid pathway and its implication in Alzheimer’s disease. Neurobiology of Aging 2004; 25:63.
  34. Iqbal K, Liang Li, Sengupta A, Iqbal IG. Memantine restores the okadaic Acid induced changes in the activities of protein phosphatase-2A in rat hippocampal slices in culture. Eur Neuropsychopharmacol 2003; 13(Suppl 4):S393-394.
  35. Li L, Sengupta A, Haque N, Grundke-Iqbal I, Iqbal K. Memantine inhibits and reserves the Alzheimer type abnormal hyperphosphorylation of tau and associated neurodegeneration. FEBS Letters 556 (2004):261-269.
  36. Wenk GL, Zajaczkowski W, Danysz W. Neuroprotection of acetylcholinergic basal forebrain neurons by memantine and neurokinin B. Behav Brain Res 1997; 83:129-33.
  37. Miguel-Hidalgo JJ, Alvarez XA, Quack G. Neuroprotection by memantine against neurodegeneration induced by beta-amyloid(1-40). Brain Res 2002 20; 958:210-221.
  38. Miguel-Hidalgo JJ, Paul I, Wanzo V, Banerjee P. Memantine prevents Aβ 1-40-induced apoptotic cell death in the rat hippocampus. Neurobiology of Aging 2004; 25 (S2):415.
  39. Barnes CA, Danysz W, Parsons CG. Effects of the uncompetitive NMDA receptor antagonist memantine on hippocampal long term potentation, short-term exploratory modulation and spatial memory in awake, feely moving rats. Eur J Neurosci 1996; 8:565-71.
  40. Tanila H, Minkeviciene R, Banerjee P. Behavioral effects of subchronic memantine treatment in APP/PS1 double mutant mice modeling Alzheimer’s disease. Eur Neuropsychopharmacol 2003; 13(Suppl 4):S392-392.
  41. Minkeviviene R, Banerjee P, Tanila H. Memantine improves spatial learning in a transgenic Mouse model of Alzheimer’s disease. J Pharmacol Exp Ther. 2004, in press.
  42. Göertelmeyer R, Erbler H. Memantine in the treatment of mild to moderate dementia syndrome. Arzneimittelforschung 1992; 42:904-13.
  43. Pantev M, Ritter R, Göertelmeyer R. Clinical and behavioural evaluation in long term care patients with mild to moderate dementia under memantine treatment. Zeitschrift für Gentopsychologie und-psychiatrie 1993; 6:103-17.
  44. Winblad B, Poritis N. Memantine in severe dementia: results of the M-best study (benefit and efficacy in severely demented patients during treatment with memantine). Int J Geriatr Psychiatry 1999; 14:135-46.
  45. Reisberg B, Doody R, Söffler A y col. Memantine in moderate to severe Alzheimer’s disease. New England Journal of Medicine 2003; 348:1333-41.
  46. Rive B, Vercelleto M, Delamarre Damier F, Cochran J. Memantine enhances autonomy in moderate to severe Alzheimer’s disease. International Journal of Geriatric Psychiatry 2004; 19:458-464.
  47. Reisberg B, Möbius HJ, Schmidtt F, Doody R. Long term efficacy and safety benefits from treatment with the NMDA antagonist memantine. European Neuropsychopharmacology 2003; 13(S4):S388-S389.
  48. Pomara N, Peskind ER, Potkin SG, McDonald S, Xie Y, Gergel I. Memantine monotherapy is effective and safe for the treatment of mild to moderate Alzheimer’s disease: a randomised controlled trial. Neurobiology of Aging 2004; 25(S2):19.
  49. Potkin SG, McDonald S, Gergel I, Alava G, Keator DB, Fallon JH. Memantine monotherapy increases brain metabolism (PET) and effectively treats mild to moderate Alzheimer’s disease. Neurobiology of Aging 2004; 25(S2):384.
  50. Tariot PN, Doody RS, Peskind ER, Winblad B, Stöffler A, Graham MS, McDonald S. Memantine treatment for mild to severe Alzheimer’s disease: clinical trials summary. Neurobiology of Aging 2004; 25(S2):99.
  51. Möbius HJ. Pharmacological rationale for memantine in chronic cerebral hypoperfusion, especially vascular dementia. Alzheimer Dis Assoc Disord 1999; 13 (Suppl 3):S172-8.
  52. Wilcock G, Möbius HJ, Stöffler A. A double blind, placebo controlled multicenter study of Memantine in mild to moderate vascular dementia (MMM500). Int Clin Psychopharm 2002; 17(6):297-305.
  53. Orgogozo JM, Rigaud AS, Stoeffler A y col. Efficacy and safety of Memantine in patients with mild to moderated vascular dementia. Stroke 2002; 33:1834-9.
  54. Mobius HJ, Stöfler A. Memantine in vascular dementia. Int Psychogeriatr 2003;15 (S1):207-13.
  55. Periclou A, Ventura D, Sherman T y col. Pharmakokinetic study of memantine and donepezil in healthy young subjects. Eur Neuropsychopharmacol 2003; 13(Suppl 4):S398.
  56. Tariot PN, Farlow MR, Grossberg GT y col. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA 2004; 291:317-24.
Título español
Resumen
 Palabras clave
 Bibliografía
 Artículo completo
(exclusivo a suscriptores)
 Autoevaluación
  Tema principal en SIIC Data Bases
 Especialidades

  English title
  Abstract
  Key words
Full text
(exclusivo a suscriptores)

Autor 
Artículos
Correspondencia

Patrocinio y reconocimiento
Imprimir esta página
 
 
 
 
 
 
 
 
 
 
 
 
Está expresamente prohibida la redistribución y la redifusión de todo o parte de los contenidos de la Sociedad Iberoamericana de Información Científica (SIIC) S.A. sin previo y expreso consentimiento de SIIC.
ua31618
Acerca de SIIC   Estructura de SIIC   Fuentes informativas  

Sociedad Iberoamericana de Información Científica

Copyright siicsalud© 1997-2024 ISSN siicsalud: 1667-9008
ua31517